시장보고서
상품코드
1274197

세계의 HLA 타이핑 시장 예측(-2028년) : 제품 및 서비스(시약 및 소모품, 기기, 소프트웨어 및 서비스), 기술(분자 어세이 기술, 비분자 어세이 기술), 용도(진단, 연구용), 최종 사용자별, 지역별

HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecast to 2028

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 217 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 HLA 타이핑 시장 규모는 2022년 14억 달러에서 2028년 21억 달러에 달할 것으로 예상되며, 예측 기간 중 6.5%의 CAGR을 나타낼 것으로 예상됩니다.

감염증, 이식편 거부반응, 자가면역질환, 암을 조기에 진단할 수 있는 임상진단법의 필요성과 강력한 수요가 연구 활동 증가를 지원하고 있으며, Journal of Human Genetics(2015)에 따르면 면역에 관여하는 인간 백혈구 항원(HLA) 분자에 대한 연구는 NGS 기술로부터 큰 혜택을 받고 있습니다. 이처럼 NGS 기술은 완전한 HLA 시퀀싱 메커니즘을 가능하게 하고, 전사, 유전자 발현 조절, 후성유전학 등 HLA 유전자 조절에 대한 이해를 용이하게 하여, NGS를 이용한 여러 가지 고처리량 HLA 타이핑 방법이 개발되었습니다. 이에 따라 정부 기관과 민간 기업들은 피험자 후보의 유전자 프로파일링과 교차 매칭을 위한 연구 활동을 지원하게 되었습니다.

"2022년, 분자 어세이 기술 부문이 시장에서 가장 큰 점유율을 차지할 것"

2022년에는 분자 어세이 기술 부문이 가장 높은 점유율을 차지할 것으로 예상됩니다. 이 분야의 높은 시장 점유율은 실시간 시료 분석, 다중 시료 검사 기능, 높은 절차 유효성, 짧은 소요 시간 등 분자 어세이 기술이 제공하는 이점에 기인합니다.

"2022년, 시약 및 소모품이 가장 큰 비중을 차지할 것"

제품 및 서비스 유형별로는 소모품 및 시약 부문이 2022년 HLA 타이핑 시장에서 가장 높은 점유율을 차지할 것으로 보고되고 있으며, HLA 타이핑에서 시약 및 소모품의 사용 증가, 연구에서의 시약 및 소모품 수용 확대, 주요 지역에서의 초기 효과적인 치료 계획 및 이식 진단에 대한 환자의 중요성 증가가 예측 기간 중 이 부문 시장 성장을 주도할 것으로 예상됩니다.

"북미의 HLA 타이핑 시장은 예측 기간 중 가장 높은 성장률을 보일 것으로 예상된다."

북미는 2022년 HLA 타이핑 시장에서 45.0%의 가장 큰 점유율을 차지할 것으로 예상됩니다. 북미의 높은 점유율은 개발된 진단 툴의 채택 증가, 캐나다와 미국의 만성질환 발생률 및 유병률 증가, 기술 개발의 발전에 기인합니다.

한편, 아시아태평양은 향후 몇 년 동안 큰 성장을 보일 것으로 예상됩니다. 아시아태평양의 HLA 타이핑 시장은 주로 아시아 국가의 병원 수 증가와 정부의 적극적인 노력으로 인해 예측 기간 중 7.5%의 CAGR을 나타낼 것으로 예상됩니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
  • Porter's Five Forces 분석
  • 규제 분석
  • HLA 타이핑 시장 : 에코시스템 매핑
  • 밸류체인 분석
  • 공급망 분석
  • 주요 이해관계자와 구입 기준
  • 특허 분석
  • HLA 타이핑 시장에 대한 불황의 영향

제6장 HLA 타이핑 시장 : 제품·서비스별

  • 서론
  • 시약·소모품
  • 기기
  • 소프트웨어·서비스

제7장 HLA 타이핑 시장 : 기술별

  • 서론
  • 분자 어세이 기술
  • 비분자 어세이 기술

제8장 HLA 타이핑 시장 : 용도별

  • 서론
  • 진단 용도
    • 도너·수취인 크로스 매칭
    • 감염증 검사
    • 암 진단·예방
    • 수혈 요법
    • 기타
  • 연구 용도

제9장 HLA 타이핑 시장 : 최종사용자별

  • 서론
  • 상용 서비스 프로바이더
  • 병원·이식 센터
  • 연구소·학술기관

제10장 HLA 타이핑 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카

제11장 경쟁 구도

  • 서론
  • 주요 기업이 채택한 전략
  • 시장 점유율 분석
  • 경쟁 리더십 매핑
  • 스타트업/중소기업 기업 평가 매트릭스(2021년)
  • 경쟁 벤치마킹
  • 경쟁 시나리오

제12장 기업 개요

  • 주요 기업
    • BD
    • BIO-RAD LABORATORIES, INC.
    • F. HOFFMAN-LA ROCHE LTD.
    • CAREDX, INC.
    • HOLOGIC, INC.
    • ILLUMINA, INC.
    • IMMUCOR, INC.
    • OMIXON INC.
    • QIAGEN N.V.
    • TAKARA BIO INC.
    • THERMO FISHER SCIENTIFIC
    • BIOFORTUNA LIMITED
    • GENDX
  • 기타 기업
    • FUJIREBIO
    • CREATIVE BIOLABS
    • ALPHA BIOTECH LIMITED
    • BAG DIAGNOSTICS GMBH
    • HANSA BIOPHARMA AB
    • HISTOGENETICS LLC
    • PACBIO
    • TBG DIAGNOSTICS LIMITED
    • INNO-TRAIN DIAGNOSTIK GMBH
    • KRISHGEN BIOSYSTEMS

제13장 부록

KSA 23.05.30

The HLA typing market is projected to reach USD 2.1 billion in 2028 from USD 1.4 billion in 2022 with a CAGR of 6.5% during the forecast period. The need and strong demand for clinical diagnostic procedures that can provide early diagnosis of infectious diseases, graft rejections, autoimmune diseases, and cancer have supported rising research activities. According to the Journal of Human Genetics (2015), research on the human leukocyte antigen (HLA) molecule (involved in immunity) has benefitted greatly from NGS technologies. Thus, several high-throughput HLA-typing methods using NGS have been developed, as NGS technology enables complete HLA sequencing mechanisms, facilitating the understanding of HLA gene modulation, including transcription, regulation of gene expression, and epigenetics. Thus, government organizations and private players increasingly support research activities that target gene profiling and cross-matching in prospective subjects.

"The molecular assay technologies segment to hold the largest share of the market in 2022"

In 2022, he molecular assay technologies segment was projected to account for the highest share. The high market share of the segment is credited to the profits of molecular assay technologies like real-time sample analysis multi-sample study capabilities, high procedural efficacy, , and low turnaround times.

"The reagents & consumables is holding the largest share of the market in 2022"

Based on product & service, The consumables & reagents segment reported for the highest share among all the three of the HLA typing market in 2022. The increasing use of reagents & consumables in HLA typing; the increasing acceptance of reagents & consumables in research studies; growing patient importance on early and effective treatment planning transplantation diagnosis over major geographies are predictable to determine market growth for this segment over the forecast period.

"The HLA Typing market in North America region is projected to witness the highest growth over the forecast period."

North America reported the largest share of 45.0% of the HLA typing market in 2022. This highest share of North America is credited to the increased adoption of developed diagnostics tools, rising incidence and prevalence of chronic disorders in Canada and the US and growing technological developments.

While APAC is expected to witness significant growth in the coming years. The HLA typing market in the APAC region is expected to register a CAGR of 7.5% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
  • By Designation: C-level-27%, Director-level-18and Others-55%
  • By Region: North America-35.3%, Europe-20%, Asia Pacific-15%, Latin America-10%, and the Middle East & Africa-5%

The prominent player in HLA typing market are Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMerieux S.A. (France). Other players in the market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others

Research Coverage

This report studies the in HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market..
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 GEOGRAPHIES COVERED
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 HLA TYPING MARKET: RESEARCH METHODOLOGY
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
      • 2.1.2.3 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
  • 2.8 HLA TYPING MARKET: RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 7 HLA TYPING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 8 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 HLA TYPING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 HLA TYPING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD

4 PREMIUM INSIGHTS

  • 4.1 HLA TYPING MARKET OVERVIEW
    • FIGURE 12 INCREASING NUMBER OF ORGAN TRANSPLANTATIONS AND RISING ADOPTION OF DONOR RECIPIENT CROSS-MATCHING TO DRIVE MARKET
  • 4.2 HLA TYPING MARKET, BY DIAGNOSTIC APPLICATIONS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 DONOR RECIPIENT CROSS-MATCHING SEGMENT TO DOMINATE DIAGNOSTIC APPLICATIONS DURING FORECAST PERIOD
  • 4.3 HLA TYPING MARKET: ASIA PACIFIC, BY PRODUCT & SERVICE (2022)
    • FIGURE 14 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA
  • 4.4 HLA TYPING MARKET: GEOGRAPHICAL SNAPSHOT
    • FIGURE 15 CHINA TO DOMINATE MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising number of organ transplantation procedures
      • 5.2.1.2 Rising technological advancements in HLA typing
      • 5.2.1.3 Increasing funding investments for research activities
    • TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR HLA TYPING PRODUCTS, 2019-2022
      • 5.2.1.4 Growing prevalence of infectious diseases
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of HLA typing products
    • TABLE 3 COST OF ASSAYS FOR KEY NGS AND PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2020)
      • 5.2.2.2 Limited reimbursements for target procedures
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising adoption of cross-matching and chimerism testing procedures
      • 5.2.3.2 Growing awareness of organ donations
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited number of organ donations and long waiting lists for transplantations
      • 5.2.4.2 Shortage of skilled professionals
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 HLA TYPING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 REGULATORY ANALYSIS
    • 5.4.1 NORTH AMERICA
      • 5.4.1.1 US
    • TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.4.1.2 Canada
    • TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
    • 5.4.2 EUROPE
    • 5.4.3 ASIA PACIFIC
      • 5.4.3.1 Japan
    • TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
      • 5.4.3.2 China
    • TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
      • 5.4.3.3 India
  • 5.5 HLA TYPING MARKET: ECOSYSTEM MAPPING
    • FIGURE 17 ECOSYSTEM COVERAGE
  • 5.6 VALUE CHAIN ANALYSIS
    • 5.6.1 RESEARCH AND DEVELOPMENT
    • 5.6.2 MANUFACTURING AND ASSEMBLY
    • 5.6.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
    • FIGURE 18 VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
    • 5.7.1 PROMINENT COMPANIES
    • 5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES
    • FIGURE 19 SUPPLY CHAIN ANALYSIS
  • 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
    • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HLA TYPING PRODUCTS
    • 5.8.2 BUYING CRITERIA
    • FIGURE 21 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS
    • TABLE 11 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS
  • 5.9 PATENT ANALYSIS
    • FIGURE 22 TOP 10 PATENT APPLICANTS FOR HLA TYPING
  • 5.10 IMPACT OF RECESSION ON HLA TYPING MARKET

6 HLA TYPING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 12 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 REAGENTS & CONSUMABLES
    • 6.2.1 WIDE APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES TO DRIVE MARKET
    • TABLE 13 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 GROWING ADOPTION OF PCR AND NGS INSTRUMENTS AMONG CROS AND HOSPITALS TO FUEL MARKET
    • TABLE 14 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 RISING DEMAND FOR AUTOMATION AND DIGITALIZATION IN LAB PROCEDURES TO DRIVE MARKET
    • TABLE 15 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 HLA TYPING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 16 HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 MOLECULAR ASSAY TECHNOLOGIES
    • TABLE 17 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 18 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 19 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 20 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 21 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1 PCR-BASED MOLECULAR ASSAYS
    • TABLE 22 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 23 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021-2028(USD MILLION)
    • TABLE 24 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 25 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 26 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.1.1 Sequence-specific Primer-PCR
        • 7.2.1.1.1 Expanding distribution channels of key PCR manufacturers to support market growth
    • TABLE 27 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.1.2 Sequence-specific Oligonucleotide-PCR
        • 7.2.1.2.1 Rising need for SSO-PCR-based molecular assays in disease diagnosis to drive market
    • TABLE 28 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.1.3 Real-time PCR
        • 7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to support market growth
    • TABLE 29 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.1.4 Other PCR-based molecular assays
    • TABLE 30 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
    • TABLE 31 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 32 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 33 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 34 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 35 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.2.1 Sanger sequencing
        • 7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology to drive segment growth
    • TABLE 36 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.2.2 Next-generation Sequencing
        • 7.2.2.2.1 High scalability, low turnaround time, and high throughput capabilities to drive segment growth
    • TABLE 37 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
      • 7.2.2.3 Other sequencing-based molecular assays
    • TABLE 38 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
    • 7.3.1 HIGH PREFERENCE OF MOLECULAR-BASED TECHNIQUES TO RESTRAIN MARKET
    • TABLE 39 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 40 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 41 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 42 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

8 HLA TYPING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 43 HLA TYPING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 8.2 DIAGNOSTIC APPLICATIONS
    • TABLE 44 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 45 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.1 DONOR-RECIPIENT CROSS-MATCHING
      • 8.2.1.1 Rising need for histocompatibility cross-matching in organ transplantation to drive market
    • TABLE 46 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.2 INFECTIOUS DISEASE TESTING
      • 8.2.2.1 Rising burden of infectious diseases to drive adoption of HLA antigen screening
    • TABLE 47 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.3 CANCER DIAGNOSIS & PREVENTION
      • 8.2.3.1 Wide availability of advanced NGS techniques to drive adoption of HLA typing in cancer diagnostics
    • TABLE 48 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.4 TRANSFUSION THERAPY
      • 8.2.4.1 Minimal risk of fatal disorders during blood transfusions to drive adoption of HLA typing
    • TABLE 49 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 2021-2028(USD MILLION)
    • 8.2.5 OTHER DIAGNOSTIC APPLICATIONS
    • TABLE 50 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 RESEARCH APPLICATIONS
    • 8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING TO DRIVE MARKET
    • TABLE 51 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

9 HLA TYPING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 52 HLA TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 COMMERCIAL SERVICE PROVIDERS
    • 9.2.1 RISING ESTABLISHMENT OF REFERENCE LABORATORIES IN EMERGING ECONOMIES TO DRIVE MARKET
    • TABLE 53 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 HOSPITALS AND TRANSPLANT CENTERS
    • 9.3.1 INCREASING DEMAND FOR ADVANCED EQUIPMENT IN HOSPITALS TO DRIVE MARKET
    • TABLE 54 HLA TYPING MARKET FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
    • 9.4.1 RISING GOVERNMENT SUPPORT FOR CANCER RESEARCH TO BOOST MARKET GROWTH
    • TABLE 55 HLA TYPING MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021-2028(USD MILLION)

10 HLA TYPING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 56 HLA TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 23 HLA TYPING MARKET: NORTH AMERICA SNAPSHOT
    • TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: HLA TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 High volume of stem cell and bone marrow transplantation procedures to drive market
    • TABLE 63 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN US, 2021-2022
    • TABLE 64 NEW CANCER CASES IN US, 2021
    • TABLE 65 US: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 66 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 High prevalence of cancer to drive adoption of HLA typing
    • TABLE 68 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 69 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 70 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 71 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 75 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: HLA TYPING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 77 EUROPE: HLA TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Strong presence of established manufacturers for HLA typing products to drive market
    • TABLE 78 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 2020-2021
    • TABLE 79 TARGET DISEASE INCIDENCE IN GERMANY (2021)
    • TABLE 80 NEW CANCER CASES IN GERMANY, BY ORGAN (2021)
    • TABLE 81 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 82 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 83 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Rising prevalence of autoimmune diseases to drive market
    • TABLE 84 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN UK, 2021-2022
    • TABLE 85 TARGET DISEASE INCIDENCE IN UK, 2021
    • TABLE 86 NEW CANCER CASES IN UK, 2021
    • TABLE 87 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 88 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 89 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rising organ rejection rate to drive market
    • TABLE 90 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, 2021-2022
    • TABLE 91 NEW CANCER CASES IN FRANCE, 2021
    • TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 93 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, 2021-2028 (USD MILLION)
    • TABLE 94 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Increasing acceptance of molecular assay technologies for personalized medicine to drive market
    • TABLE 95 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 96 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising number of solid-organ transplantation procedures to support market growth
    • TABLE 98 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 99 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 100 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 101 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 102 REST OF EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 REST OF EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 24 HLA TYPING MARKET: ASIA PACIFIC SNAPSHOT
    • TABLE 104 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 107 ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Rising adoption of HLA typing for donor-recipient screening to drive market
    • TABLE 111 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, 2021-2022
    • TABLE 112 NEW CANCER CASES IN CHINA, 2021
    • TABLE 113 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 114 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.4.2 INDIA
      • 10.4.2.1 Government initiatives to provide free availability of HLA typing products to drive market
    • TABLE 116 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, 2021-2022
    • TABLE 117 NEW CANCER CASES IN INDIA, 2021
    • TABLE 118 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 119 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Increasing budgetary allocations for healthcare to support market growth
    • TABLE 121 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, 2021-2022
    • TABLE 122 NEW CANCER CASES IN JAPAN, 2021
    • TABLE 123 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 124 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 Rising prevalence of coeliac disease to drive adoption of HLA typing
    • TABLE 126 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, 2021-2022
    • TABLE 127 NEW CANCER CASES IN AUSTRALIA, 2021
    • TABLE 128 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 129 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Rising adoption of next-generation exome sequencing to drive market
    • TABLE 131 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 132 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 133 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 134 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 135 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 137 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 138 LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 139 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 LATIN AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 142 LATIN AMERICA: HLA TYPING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 143 LATIN AMERICA: HLA TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 Supportive government regulations for adoption of advanced technologies to drive market
    • TABLE 144 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, 2021-2022
    • TABLE 145 NEW CANCER CASES IN BRAZIL, 2021
    • TABLE 146 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 147 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth
    • TABLE 149 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, 2021-2022
    • TABLE 150 NEW CANCER CASES IN MEXICO, 2021
    • TABLE 151 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 152 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 154 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 155 REST OF LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 156 REST OF LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST AND AFRICA
    • 10.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FUEL MARKET
    • TABLE 157 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 158 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 161 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 162 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 163 HLA TYPING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 25 HLA TYPING MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
  • 11.4 COMPETITIVE LEADERSHIP MAPPING
    • 11.4.1 STARS
    • 11.4.2 EMERGING LEADERS
    • 11.4.3 PERVASIVE PLAYERS
    • 11.4.4 PARTICIPANTS
    • FIGURE 26 HLA TYPING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
  • 11.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2021)
    • 11.5.1 PROGRESSIVE COMPANIES
    • 11.5.2 RESPONSIVE COMPANIES
    • 11.5.3 DYNAMIC COMPANIES
    • 11.5.4 STARTING BLOCKS
    • FIGURE 27 HLA TYPING MARKET: COMPANY EVALUATION MATRIX FOR SMES/STARTUPS, 2021
  • 11.6 COMPETITIVE BENCHMARKING
    • TABLE 164 HLA TYPING MARKET: PRODUCT ANALYSIS FOR KEY PLAYERS
    • TABLE 165 HLA TYPING MARKET: APPLICATION FOOTPRINT ANALYSIS FOR KEY PLAYERS
    • TABLE 166 HLA TYPING MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
  • 11.7 COMPETITIVE SCENARIO
    • 11.7.1 PRODUCT LAUNCHES
    • TABLE 167 HLA TYPING MARKET: PRODUCT LAUNCHES (2019-2022)
    • 11.7.2 DEALS
    • TABLE 168 HLA TYPING MARKET: DEALS (2019-2022)

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 BD
    • TABLE 169 BD: COMPANY OVERVIEW (2021)
    • FIGURE 28 BD: COMPANY SNAPSHOT (2021)
    • 12.1.2 BIO-RAD LABORATORIES, INC.
    • TABLE 170 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 29 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.3 F. HOFFMAN-LA ROCHE LTD.
    • TABLE 171 F. HOFFMAN-LA ROCHE LTD: COMPANY OVERVIEW (2021)
    • FIGURE 30 F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
    • 12.1.4 CAREDX, INC.
    • TABLE 172 CAREDX, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 31 CAREDX, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.5 HOLOGIC, INC.
    • TABLE 173 HOLOGIC, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 32 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 ILLUMINA, INC.
    • TABLE 174 ILLUMINA, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.7 IMMUCOR, INC.
    • TABLE 175 IMMUCOR, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 34 IMMUCOR, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.8 OMIXON INC.
    • TABLE 176 OMIXON INC.: COMPANY OVERVIEW (2021)
    • 12.1.9 QIAGEN N.V.
    • TABLE 177 QIAGEN N.V.: COMPANY OVERVIEW (2021)
    • FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.10 TAKARA BIO INC.
    • TABLE 178 TAKARA BIO INC.: COMPANY OVERVIEW (2021)
    • FIGURE 36 TAKARA BIO, INC: COMPANY SNAPSHOT (2021)
    • 12.1.11 THERMO FISHER SCIENTIFIC
    • TABLE 179 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021)
    • FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 12.1.12 BIOFORTUNA LIMITED
    • 12.1.13 GENDX
    • TABLE 180 GENDX: COMPANY OVERVIEW (2021)
  • 12.2 OTHER PLAYERS
    • 12.2.1 FUJIREBIO
    • 12.2.2 CREATIVE BIOLABS
    • 12.2.3 ALPHA BIOTECH LIMITED
    • 12.2.4 BAG DIAGNOSTICS GMBH
    • 12.2.5 HANSA BIOPHARMA AB
    • 12.2.6 HISTOGENETICS LLC
    • 12.2.7 PACBIO
    • 12.2.8 TBG DIAGNOSTICS LIMITED
    • 12.2.9 INNO-TRAIN DIAGNOSTIK GMBH
    • 12.2.10 KRISHGEN BIOSYSTEMS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제